AstraZeneca stock heads into the open after a 0.32 percent slip

At the close on September 21, 2026, AstraZeneca stock slipped 0.32 percent in London after closing at GBP 125.07. The shares traded between GBP 123.64 and GBP 125.06, while the FTSE 100 finished at 10,753 points.

AstraZeneca stock closed at GBP 125.07 on the London Stock Exchange on September 21, 2026, down 0.32 percent. The shares finished near the middle of an intraday band that ran from GBP 123.64 to GBP 125.06, with volume at 236,251 shares.

At the first company mention, AstraZeneca PLC (ISIN GB0009895292) moved lower after Reuters reported that the European Union's drug regulator backed Enhertu for early breast cancer. The FTSE 100 rose to 10,753 points in the same session, leaving the shares modestly behind the benchmark.

Within the same update, Reuters said the CHMP opinion was based on the DESTINY-Breast05 trial and cited a 53 percent reduction in invasive disease recurrence or death. The stock also ended far below its 52-week high of GBP 157.30, reached on February 19, 2026, and above its 52-week low of GBP 107.84 from September 27, 2025.

Today and the next sessions

Today, AstraZeneca's EU approval story for Enhertu may stay in focus after the weekend recommendation. Reuters also said the company is working with Daiichi Sankyo on the treatment, which could keep the news flow around oncology in view during the session.